SG Americas Securities LLC Makes New Investment in Embecta Corp. $EMBC

SG Americas Securities LLC acquired a new stake in shares of Embecta Corp. (NASDAQ:EMBC) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 435,842 shares of the company’s stock, valued at approximately $5,178,000.

A number of other hedge funds also recently made changes to their positions in EMBC. Larson Financial Group LLC grew its position in Embecta by 368.6% in the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after acquiring an additional 1,574 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Embecta by 542.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after purchasing an additional 6,224 shares in the last quarter. Wexford Capital LP purchased a new stake in Embecta during the third quarter valued at about $94,000. Humankind Investments LLC bought a new stake in Embecta during the second quarter worth about $111,000. Finally, iSAM Funds UK Ltd purchased a new position in shares of Embecta in the 3rd quarter worth about $115,000. 93.83% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. BTIG Research reiterated a “buy” rating and set a $25.00 price objective on shares of Embecta in a research report on Friday, February 6th. Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $18.50.

Embecta Stock Down 0.6%

Shares of EMBC opened at $8.79 on Thursday. The stock has a market capitalization of $520.54 million, a P/E ratio of 3.71 and a beta of 1.14. Embecta Corp. has a twelve month low of $8.47 and a twelve month high of $15.55. The firm has a fifty day simple moving average of $9.86 and a two-hundred day simple moving average of $12.04.

Embecta (NASDAQ:EMBC) last released its quarterly earnings data on Thursday, February 5th. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.04. The firm had revenue of $261.20 million for the quarter, compared to analysts’ expectations of $258.07 million. Embecta had a net margin of 12.92% and a negative return on equity of 26.66%. The company’s revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.65 earnings per share. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. Sell-side analysts expect that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 17th. Investors of record on Friday, February 27th were issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date was Friday, February 27th. Embecta’s payout ratio is currently 25.32%.

Embecta Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.